Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

No FDAer For Commissioner, Interim or Otherwise, Rep. Stupak Urges Obama

Executive Summary

The pharmaceutical industry has an unusual new ally in its effort to achieve some of its goals during the presidential transition: Rep. Bart Stupak, D-Mich

You may also be interested in...



Woodcock Doesn't Want To Be Commissioner – But Has Some Ideas

CDER director believes some management improvements could be made in the executive suite, but she does not aspire to run FDA.

PDUFA Needs Mid-Cycle Correction System As Part Of Reauthorization, Industry Says

Industry wants to place benchmarks in PDUFA that would allow for changes mid-stream, instead of waiting until the end of each five-year cycle.

PDUFA Needs Mid-Cycle Correction System As Part Of Reauthorization, Industry Says

Industry wants to place benchmarks in PDUFA that would allow for changes mid-stream, instead of waiting until the end of each five-year cycle.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS050416

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel